GALWAY, Ireland--(BUSINESS WIRE)--Nearly 18 months of data from Cappella’s Sideguard I & II in-man trials were released two weeks ago at the TCT industry breakfast on Monday, October 13, marking an important milestone for Cappella. More than 170 professionals from the cardiovascular community gathered to hear what the leading panel of interventional cardiologists had to say about Cappella’s self-expanding side branch heart stent.
